Hypertensive Emergency: Parenteral Antihypertensives and Population Data.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Farley TM;Farley TM;Farley TM
  • Source:
    Current hypertension reports [Curr Hypertens Rep] 2023 Dec; Vol. 25 (12), pp. 423-428. Date of Electronic Publication: 2023 Nov 17.
  • Publication Type:
    Journal Article; Review
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Current Science, Inc Country of Publication: United States NLM ID: 100888982 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1534-3111 (Electronic) Linking ISSN: 15226417 NLM ISO Abbreviation: Curr Hypertens Rep Subsets: MEDLINE
    • Publication Information:
      Original Publication: Philadelphia, PA : Current Science, Inc., c1999-
    • Subject Terms:
      Labetalol*/therapeutic use ; Hypertension*/drug therapy ; Hypertensive Encephalopathy*; Humans ; Antihypertensive Agents/therapeutic use ; Nicardipine/therapeutic use ; Emergencies ; Randomized Controlled Trials as Topic
    • Abstract:
      Purpose of Review: Review parenteral therapeutic choices in treatment of hypertensive crises by mechanism of action and summarize recent literature on the management of hypertensive crises.
      Recent Findings: Recent data have documented the safety and efficacy of labetalol and nicardipine in treatment of hypertensive crises as well as characterized the hypertensive emergency population to a much greater extent. Based on recent data, hypertensive emergencies are seen in 0.5% of all emergency room visits. Ischemic stroke and heart failure/pulmonary edema are the most common forms of organ damage seen in hypertensive emergencies. There are many therapeutic choices in treatment of hypertensive crises with varied mechanisms of action. Large randomized, controlled trial evidence is lacking in this therapeutic area; however, recent data have documented the safety and efficacy of labetalol and nicardipine.
      (© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
    • Contributed Indexing:
      Keywords: HMOD; Hypertension; Hypertensive emergency; Organ damage; Parenteral therapy
    • Accession Number:
      0 (Antihypertensive Agents)
      CZ5312222S (Nicardipine)
      R5H8897N95 (Labetalol)
    • Publication Date:
      Date Created: 20231117 Date Completed: 20231206 Latest Revision: 20240529
    • Publication Date:
      20250114
    • Accession Number:
      10.1007/s11906-023-01280-2
    • Accession Number:
      37975973